Skip to Main Content
Table 3—

The association of baseline clinical data and lipid variables with declining renal function in patients with macroalbuminuria

NonprogressorsProgressors
n 19 12 
Baseline AER (geometric mean) (μg/min) 446 398 
Baseline CrCl (ml/min per 1.73 m272 ± 6 66 ± 4 
End point CrCl (ml/min per 1.73 m267 ± 9 26 ± 6* 
Sex (% male) 35 58* 
HbA1c (%) 8.1 ± 0.3 8.5 ± 0.3 
Systolic blood pressure (mmHg) 132 ± 4 145 ± 6* 
Diastolic blood pressure (mmHg) 87 ± 2 82 ± 2 
Pulse pressure (mmHg) 44 ± 3 61 ± 6* 
Smoking at baseline (%) 12 50* 
Lipid-lowering therapy at end point (%) 17 33 
LDL cholesterol (mmol/l) 3.2 ± 0.2 3.1 ± 0.2 
Non-HDL cholesterol (mmol/l) 3.7 ± 0.3 3.7 ± 0.2 
Total triglycerides (mmol/l) 0.97 ± 0.07 1.05 ± 0.10 
HDL cholesterol (mmol/l) 1.5 ± 0.1 1.7 ± 0.1 
LDL size (nm) 26.2 ± 0.1 25.3 ± 0.2* 
Percentage VLDL triglyceride (%) 47 ± 3 47 ± 2 
LPL15 (μmol FFA · ml−1 · h−137 ± 3 39 ± 4 
HL15 (μmol FFA · ml−1 · h−130 ± 2 29 ± 4 
NonprogressorsProgressors
n 19 12 
Baseline AER (geometric mean) (μg/min) 446 398 
Baseline CrCl (ml/min per 1.73 m272 ± 6 66 ± 4 
End point CrCl (ml/min per 1.73 m267 ± 9 26 ± 6* 
Sex (% male) 35 58* 
HbA1c (%) 8.1 ± 0.3 8.5 ± 0.3 
Systolic blood pressure (mmHg) 132 ± 4 145 ± 6* 
Diastolic blood pressure (mmHg) 87 ± 2 82 ± 2 
Pulse pressure (mmHg) 44 ± 3 61 ± 6* 
Smoking at baseline (%) 12 50* 
Lipid-lowering therapy at end point (%) 17 33 
LDL cholesterol (mmol/l) 3.2 ± 0.2 3.1 ± 0.2 
Non-HDL cholesterol (mmol/l) 3.7 ± 0.3 3.7 ± 0.2 
Total triglycerides (mmol/l) 0.97 ± 0.07 1.05 ± 0.10 
HDL cholesterol (mmol/l) 1.5 ± 0.1 1.7 ± 0.1 
LDL size (nm) 26.2 ± 0.1 25.3 ± 0.2* 
Percentage VLDL triglyceride (%) 47 ± 3 47 ± 2 
LPL15 (μmol FFA · ml−1 · h−137 ± 3 39 ± 4 
HL15 (μmol FFA · ml−1 · h−130 ± 2 29 ± 4 

Data are means ± SE unless otherwise indicated.

*

Progressors vs. nonprogressors, univariate P < 0.05.

Progressors vs. nonprogressors, adjusted P < 0.05. CrCl, creatinine clearance; FFA, free fatty acid; HL15, hepatic lipase 15 min after an intravenous bolus of heparin; LPL15, lipoprotein lipase 15 min after an intravenous bolus of heparin.

Close Modal

or Create an Account

Close Modal
Close Modal